Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Selenium sulfide is under clinical development by Azura Ophthalmics and currently in Phase II for Unspecified Ophthalmological Disorders.

CKD-510 is under development for the treatment of Charcot-Marie-Tooth disease and atrial fibrillation. It is administered through oral route.The drug candidate is a new chemical entity targeting ...

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

NVK-004 is under clinical development by Nevakar Injectables and currently in Pre-Registration for Unspecified Cardiovascular Disorders.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

VTP-500 is under clinical development by Barinthus Biotherapeutics and currently in Phase I for Middle East Respiratory Syndrome (MERS).

Dactolisib tosylate is under clinical development by Adicet Bio and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

CBP-1019 is under development for the treatment of lung cancer, non-small cell lung cancer, small-cell lung cancer, colorectal cancer, platinum resistant ovarian cancer (PROC) and pancreatic cancer.

HLC-001 is under clinical development by Human Life CORD Japan and currently in Phase II for Unspecified Respiratory Disorders.

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.